Back to results
US 2026/0308258 A1Published application
Agents that bind to cd16a and uses thereof
AssigneeAvantgen, Inc.
InventorsXiaomin FAN, Wuxiang LIAO, Christine TUMANUT
Life of this patent
Estimating the term…
Abstract
The present disclosure provides binding agents that bind to CD 16a (e.g., antibodies, multispecific antibodies, antigen binding fragments) and uses thereof.
Claims46
An antibody or fragment thereof that binds to CD16a, wherein the antibody or antigen binding fragment comprises:
- (i) a VH CDR1, a VH CDR2, and a VH CDR3 as set forth in a VH comprising the amino acid sequence of SEQ ID NO:
- 37 and a VL CDR1, a VL CDR2, and a VL CDR3 as set forth in a VL comprising the amino acid sequence of SEQ ID NO:
- 38;
- (ii) a VH CDR1, a VH CDR2, and a VH CDR3 as set forth in a VH comprising the amino acid sequence of SEQ ID NO:
- 75 and a VL CDR1, a VL CDR2, and a VL CDR3 as set forth in a VL comprising the amino acid sequence of SEQ ID NO:
- 76;
- (iii) a VH CDR1, a VH CDR2, and a VH CDR3 as set forth in a VH comprising the amino acid sequence of SEQ ID NO:
- 113 and a VL CDR1, a VL CDR2, and a VL CDR3 as set forth in a VL comprising the amino acid sequence of SEQ ID NO:
- 114;
- (iv) a VH CDR1, a VH CDR2, and a VH CDR3 as set forth in a VH comprising the amino acid sequence of SEQ ID NO:
- 151 and a VL CDR1, a VL CDR2, and a VL CDR3 as set forth in a VL comprising the amino acid sequence of SEQ ID NO:
- 152;
- (v) a VH CDR1, a VH CDR2, and a VH CDR3 as set forth in a VH comprising the amino acid sequence of SEQ ID NO:
- 189 and a VL CDR1, a VL CDR2, and a VL CDR3 as set forth in a VL comprising the amino acid sequence of SEQ ID NO:
- 190;
- (vi) a VH CDR1, a VH CDR2, and a VH CDR3 as set forth in a VH comprising the amino acid sequence of SEQ ID NO:
- 227 and a VL CDR1, a VL CDR2, and a VL CDR3 as set forth in a VL comprising the amino acid sequence of SEQ ID NO:
- 228;
- (vii) a VH CDR1, a VH CDR2, and a VH CDR3 as set forth in a VH comprising the amino acid sequence of SEQ ID NO:
- 265 and a VL CDR1, a VL CDR2, and a VL CDR3 as set forth in a VL comprising the amino acid sequence of SEQ ID NO:
- 266;
- (vii) a VH CDR1, a VH CDR2, and a VH CDR3 as set forth in a VH comprising the amino acid sequence of SEQ ID NO:
- 303 and a VL CDR1, a VL CDR2, and a VL CDR3 as set forth in a VL comprising the amino acid sequence of SEQ ID NO:
- 304;
- or
- (ix) a VH CDR1, a VH CDR2, and a VH CDR3 as set forth in a VH comprising the amino acid sequence of SEQ ID NO:
- 341 and a VL CDR1, a VL CDR2, and a VL CDR3 as set forth in a VL comprising the amino acid sequence of SEQ ID NO:
- 342.
25 more elements
An antibody or fragment thereof that binds to CD16a, wherein the antibody or fragment thereof binds to both CD16a-F and CD16a-V.
An antibody or fragment thereof which specifically recognizes an epitope comprising the residue Asp 82 of human CD16a with an affinity for CD16a at least 10-fold higher than for CD16b.
Dependencies are inferred from the claim text.